Top

Published in:

01-05-2008 | Poster presentation

Coactivation of estrogen receptor alpha by the DEAD-box RNA helicases p68 and p72 and its role in breast cancer

Authors: FV Fuller-Pace, E Ahamed, NC Wortham, S Ali

Published in: Breast Cancer Research | Special Issue 2/2008

Excerpt

We have previously demonstrated that the DEAD-box RNA helicase p68 is an important regulator of gene expression [1, 2], whilst other groups have shown that p68 interacts with and coactivates estrogen receptor alpha (ERα) [3, 4]. The main focus of our project is to investigate the molecular mechanism of ERα coactivation by p68 and to examine the potential consequences for breast cancer development. …

Bates GJ, Nicol SM, Wilson BJ, Jacobs AM, Bourdon JC, Wardrop J, Gregory DJ, Lane DP, Perkins ND, Fuller-Pace FV: The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor. EMBO J. 2005, 24: 543-553. 10.1038/sj.emboj.7600550.CrossRefPubMedPubMedCentral

Wilson BJ, Bates GJ, Nicol SM, Gregory DJ, Perkins ND, Fuller-Pace FV: The p68 and p72 DEAD box RNA helicases interact with HDAC1 and repress transcription in a promoter-specific manner. BMC Mol Biol. 2004, 5: 11-10.1186/1471-2199-5-11.CrossRefPubMedPubMedCentral

Watanabe M, Yanagisawa J, Kitagawa H, Takeyama K, Ogawa S, Arao Y, Suzawa M, Kobayashi Y, Yano T, Yoshikawa H, Masuhiro Y, Kato S: A subfamily of RNA-binding DEAD-box proteins acts as an estrogen receptor alpha coactivator through the N-terminal activation domain (AF-1) with an RNA coactivator, SRA. EMBO J. 2001, 20: 1341-1352. 10.1093/emboj/20.6.1341.CrossRefPubMedPubMedCentral

Métivier R, Penot G, Hübner MR, Reid G, Brand H, Kos M, Gannon F: Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell. 2003, 115: 751-763. 10.1016/S0092-8674(03)00934-6.CrossRefPubMed

Title: Coactivation of estrogen receptor alpha by the DEAD-box RNA helicases p68 and p72 and its role in breast cancer
Authors: FV Fuller-Pace
E Ahamed
NC Wortham
S Ali
Publication date: 01-05-2008
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue Special Issue 2/2008
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr1900

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 2/2008

ZNF366 is a novel corepressor for estrogen receptor alpha that mediates its effects through interaction with CtBP

Interactions between BRCA2 protein and the meiosis-specific recombinase DMC1

Exploring the acceptability of, and preferences for, an ongoing support network for known BRCA1 and BRCA2 mutation carriers

Insulin-like growth factor binding protein 3 modulates epidermal growth factor (EGF)-induced growth of breast epithelial cells by altering EGF receptor internalization

Understanding and exploiting changes in O-linked glycosylation in breast cancer

RASSF2 can suppress the growth of breast cancer cell lines and is epigenetically inactivated in breast tumours

Keynote webinar | Spotlight on antibody–drug conjugates in cancer